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Summary. In 22 patients with advanced squamous cell car- 
cinoma of the head and neck we evaluated the efficacy 
and toxicity of 200 m g / m  2 cisplatin administered in 3% 
NaC1 with vigorous hydration. Six patients had previously 
untreated stage IV disease and 16 patients had recurrent 
disease, including eight with prior chemotherapy including 
low-dose cisplatin and carboplatin. Cisplatin was adminis- 
tered as a brief infusion, either 40 mg/m2/day x 5 or 
50 mg/mZ/day x4,  every 28 days. Objective responses 
were observed in 16 of 22 (73%) patients, including 5 of 6 
(83%) previously untreated patients and 11 of 16 (69%) pa- 
tients with recurrent disease. This included two complete 
responses, one confirmed pathologically. Fifty-seven 
courses of drug were administered and toxicity was moni- 
tored with serial creatinine clearance determinations, 
audiograms, and sensorimotor exams. Neuropathy and ot- 
otoxicity were dose-limiting and led to the stopping of 
treatment in 12 of the 16 responders after one to four 
courses (median three courses). Only two responding pa- 
tients continued treatment until disease progression oc- 
curred at 3 and 4 months after achieving maximum re- 
sponse. Acute, transient nephrotoxicity occurred in four 
patients; two were retreated. Moderate myelosuppression 
occurred in all patients but was not treatment-limiting. For 
most patients the maximally tolerated number of courses 
was three. The median survival time was 33.5 weeks for 
recurrent disease patients, 108 weeks for newly diagnosed 
patients. This regimen is not recommended for the pallia- 
tion of recurrent disease. However, the very high response 
rate suggests that high-dose cisplatin may have a useful 
role in induction or adjuvant chemotherapy regimens. 
Introduction 
Cisplatin is one of the few cytotoxic agents with well-esta- 
blished activity against head and neck cancer. With stan- 
dard doses of 8 0 - 1 2 0 m g / m  2 administered every 3 - 4  
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weeks, responses are observed in approximately 33% of 
recurrent disease patients and 40% of previously untreated 
patients [7, 13, 14, 16, 17]. In early phase I testing, nephro- 
toxicity was frequent and dose-limiting [2, 5, 6, 12, 15]. The 
recommended dose per course was 75-90 m g / m  2. The de- 
velopment of regimens utilizing parenteral hydration and 
furosemide and mannitol diuresis decreased the incidence 
of nephrotoxicity and led to a maximum recommended 
dose for clinical trials of 120 m g / m  2 per course [4, 11]. Re- 
cently, investigators have reported the safe administration 
of up to 200 m g / m  2 in divided doses using 3% saline as the 
diluting solution [9, 10]. In these trials no significant 
changes in creatinine clearance were observed in patients 
with normal renal function and no prior exposure to cis- 
platin. The patient population in these trials consisted pri- 
marily of young males with testicular cancer and women 
with gynecologic malignancies treated with high-dose cis- 
platin-containing combination chemotherapy. 
In January 1984, we initiated a phase II trial of high- 
dose cisplatin in patients with advanced head and neck 
cancer. The objectives were severalfold: (1) to determine 
the feasibility of administering a course of 200 m g / m  2 cis- 
platin with hypertonic saline and concomitant hydration 
to an older population of patients with head and neck can- 
cer; (2) to determine and characterize the dose-limiting 
toxicities; (3) to determine the maximum number of 
courses tolerated prior to the development of limiting toxi- 
cities; and (4) to determine the complete and partial re- 
sponse rates. 
Materials and methods 
Patients. Eligible patients had advanced, recurrent carci- 
noma arising from a primary site in the head and neck or 
had newly diagnosed stage IV disease. All patients had his- 
tologically confirmed squamous cell carcinoma, bidimen- 
sionally measurable disease, and had not received radio- 
therapy or chemotherapy within 4 weeks of study entry. 
Prior exposure to conventional dosage cisplatin was al- 
lowed. Patients were required to have a Karnofsky per- 
formance status of at least 60%, a life expectancy of at 
least 12 weeks, adequate bone marrow reserve (WBC 
>3500 cells/ixl, platelets > 100000 cells/Ixl), no evidence 
of obstructive liver disease (bilirubin < 2.0 mg%), serum 
creatinine of < 2 mg/dl  and 24-h creatinine clearance of 
> 60 ml/min. There was no age limitation; however, pa- 
tients over the age of 70 were required to have a perform- 
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ance status of at least 70% and creatinine clearance of at 
least 80 ml/min. Patients with a history of peripheral neu- 
ropathy or an abnormal sensorimotor examination were 
excluded. Adequate auditory function, determined by au- 
diometry, was required. A hearing loss in one ear could 
not exceed 30 dB at 500, 1000, and 2000 Hz. All patients 
were able to give meaningful, informed consent. This 
study was approved by the human investigations review 
boards at the University of Michigan and Ann Arbor VA 
Medical Centers. 
Treatment plan. Patients were treated with a total dose of 
200 mg/m z cisplatin repeated every 28 days. The dose was 
divided over 5 days (40 mg/m 2) or 4 days (50 mg/m 2) in an 
attempt to shorten hospitalization time. Prior to treatment, 
patients received overnight hydration with normal saline 
plus 20 mEq KC1/1 at 125 cc/h. Four hours prior to drug 
administration the hydration was increased to 250 cc/h 
and this was maintained for 4 h after treatment. The pre- 
treatment hydration rate was then resumed and the se- 
quence repeated for each daily treatment. The cisplatin 
dose was mixed in 250 cc of 3% NaC1 and infused over 
30-45 min. Twenty milligrams of furosemide was adminis- 
tered intravenously at the start of the cisplatin infusion. 
Total intake and output were carefully monitored. 
Prior to each course of cisplatin, patients underwent a 
complete physical examination which included sensorimo- 
tor testing, an audiogram, and assessment of measurable 
disease parameters. Laboratory studies included 24-h 
creatinine clearance, serum electrolytes, BUN, creatinine, 
CBC, and platelet count. During treatment, patients were 
monitored with daily serum electrolytes, BUN, and creati- 
nine determinations. CBC, platelet count, and serum mag- 
nesium were determined on days 1 and 5. Monitoring be- 
tween treatments consisted of weekly CBC and differential 
count, platelet count, serum electrolytes, creatinine, and 
Mg z+. 
Subsequent cycles were attenuated to 75% of the dose 
of the preceding cycle if the nadir WBC was less than 1500 
cells/Ixl or the nadir platelet count less than 50000 cells/~d. 
On day 28, if the WBC was less than 3500 cells/lxl or plate- 
lets were less than 100000 cells/Ill treatment was held until 
recovery. Treatment was otherwise continued until the de- 
velopment of progressive disease or the occurrence of 
other nonhematologic toxicity. Toxicity requiring study 
termination included neuropathy of at least grade 2 (de- 
fined as absent deep tendon reflexes, motor weakness, and 
peripheral nerve pain), symptomatic high-frequency hear- 
ing loss (3000-8000 Hz range) or any hearing loss in the 
speaking range (350-2000 Hz),or a drop in creatinine 
clearance to less than 60 ml/min. All patients with an 
asymptomatic high-frequency hearing loss were informed 
and consent was obtained to continue therapy. An ade- 
quate trial consisted of 4 weeks of treatment and toxicity 
monitoring. 
Complete response (CR) was defined as disappearance 
of all evidence of tumor, including normalization of X- 
rays and biochemical tests, for a minimum of 4 weeks; 
partial response (PR) as a 50% or greater decrease in the 
sum of the products of the greatest perpendicular diame- 
ters of all lesions for a minimum of 4 weeks without the 
appearance of any new lesions; stable disease as a measu- 
rable response less than that required for PR or a less than 
25% increase in the sum of the products of the greatest per- 
pendicular diameters for a minimum of 4 weeks; and pro- 
gression as unequivocal increase of at least 25% in the size 
of any measurable lesion or the appearance of new lesions. 
Results 
Twenty-two patients were treated and all were evaluable 
for response and toxicity. The first 11 patients entered into 
the trial were treated on the 5-day schedule. Patient char- 
acteristics are detailed in Table 1. Six patients with stage 
IV disease were previously untreated. Three of these pa- 
tients had bulky, unresectable disease, one had pulmonary 
metastases, and two were potentialy resectable (T2NzM 0 
tonsil, T2N3M0 hypopharynx). Two of the eight patients 
previously treated with chemotherapy had received cis- 
platin-containing adjuvant chemotherapy only. Two pa- 
tients had prior exposure to cisplatin in low dosage 
(80 mg/m z every 4 weeks) for treatment of recurrent dis- 
ease and two patients had prior exposure to carboplatin. 
The response rate according to prior treatment is 
shown in Table 2. Among the 22 patients there were two 
CR and 14 PR (73% C R +  PR). One CR in a previously un- 
treated patient was confirmed pathologically after surgical 
resection. Three of the four patients who had received 
prior cisplatin in lower doses responded. These patients 
consisted of one prior responder to a cisplatin-containing 
Table 1. Patient characteristics 
No. of patients 22 
Median age (range) 53 (24- 65) 
Median performance status (range) 70 (50-90) 
Males/females 19/3 
Prior treatment 
No treatment 6 
Surgery 12 
Radiation therapy 15 
Chemotherapy 8 
Cisplatin - 4 
Carboplatin - 2 
Primary site 
Oral cavity 4 
Oropharynx 9 




Unknown primary 1 
Sites of measurable disease 
Local-regional 17 
Local-regional + distant 3 
Distant only 2 
Table 2. Results 
Response Total No prior Recurrent 
treatment disease 
Complete (CR) 2 1 1 
Partial (PR) 14 4 10 
Stable 1 0 1 
Progression 5 1 4 
CR + PR/no. ofpts 16/22 (73%) 5/6 (83%) 11/16 (69%) 
adjuvant chemotherapy regimen and two recurrent disease 
patients, one refractory to low-dose cisplatin and one in- 
itial nonresponder. Both carboplatin-treated patients en- 
tered into the trial were nonresponders to carboplatin. One 
of these responded to high-dose cisplatin. 
A total of 57 courses of high-dose cisplatin were ad- 
ministered, 30 to patients on the 5-day treatment schedule 
and 27 to those on the 4-day schedule. Hematologic toxici- 
ty affecting all three blood elements was observed in all 
patients (Table 3). There was a trend for a delay in re- 
covery with successive doses; however, count nadirs did 
not vary appreciably after one or five courses. Nine pa- 
tients had treatment delays for prolonged recovery from 
myelosuppression. However, only four patients required a 
25% dose reduction. There was one admission for a febrile 
episode in a granulocytopenic patient who was blood-cul- 
ture negative. There was no difference in hematologic toxi- 
city between the 5-day course and the 4-day course. 
Neuropathy and ototoxicity were the most common 
nonhematologic toxicities observed (Table 4). Six patients 
developed a grade 2 peripheral neuropathy while on study. 
One of these patients, removed from study for ototoxicity 
after three courses, had further increase in his peripheral 
neuropathy off treatment, eventually becoming bedridden 
(grade 3). The time course for the development of symp- 
toms of neuropathy was variable, ranging from 2 to 5 
months from the start of cisplatin. No improvement was 
observed after stopping treatment, perhaps due to the brief 
survival time of most patients. A complete set of serial au- 
diograms was not obtained in five patients. Of the 17 sets 
evaluable, 14 showed a high-frequency hearing loss, in- 
Table 3. Hematologic toxicity 
Median nadir Median day Median day 
(range) of nadir of recovery 
(range) (range) 
WBC 2600 21 30 
(700-5800) (15-34) (22-77) 
Granulocytes 984 21 30 
(119-2540) (10-69) (21-77) 
Platelets 116 000 16 22 
(9000-206000) (11-41) (18-55) 
Hb decrease > 2.0 g -  15 patients 
Table 4. Nonhematologic toxicity 
Toxicity Median loss No. of patients 
ototoxicitya (range) 
3000-8000 Hz 45 dB (15-60) 14 







Alopecia (mild) 6 
Nephrotoxicity (Cr > 2.0 mg/dl) 4 
Seventeen evaluable patients 
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Table 5. High-dose cisplatin: reasons for study termination 
No. of patients Courses completed 
Progressive disease 8 5 a, 4 a, 2, 2, 2, 1, 1, 1 
Ototoxicity 9 3, 3, 3, 3, 3, 3, 2, 2, 1 
Neuropathy 3 4, 4, 2 
Refused treatment 1 2 
Maximum response 1 3 
Total 22 
a Concurrent neuropathy and ototoxicity 
cluding patients who also demonstrated a loss in the 
speaking range. Repeat audiograms at intervals for up to 6 
months after stopping treatment showed no reversibility in 
ototoxicity. 
Other observed toxicities were nausea and vomiting, 
grade 1-2 in 16 patients and grade 3 requiring hydration 
in one. All patients were treated with metochlopramide 
containing antiemetic regimens. Diarrhea, not clearly 
drug-related, occurred in four, and mild alopecia was no- 
ted in six patients. Transient nephrotoxicity occurred in 
f~ur  patients, with maximum creatinine levels of 6.0, 3.9, 
2.7, and 2.1 mg/dl. Two were retreated without recurrence 
of creatinine elevation above 2 mg/dl. The other two pa- 
tients were taken off study, one because of progressive dis- 
ease and the other because of ototoxicity. In four patients 
nephrotoxicity was monitored by measuring daily excre- 
tion of the tubular enzymes alanine aminopeptidase and 
N-acetyl-13-D-glucosaminidase. Enzyme and total protein 
excretion did not vary significantly from determinations 
made in patients receiving a single 100 mg/m 2 dose [15]. 
None of these four patients experienced increases in serum 
creatinine. 
The primary reason for stopping cisplatin treatment in 
the majority of responding patients (12 of 16) was the de- 
velopment of toxicity (Table 5). Six patients had progres- 
sive disease after one or two courses of cisplatin. Two pa- 
tients who had brief PR lasting 4 and 5 months respective- 
ly had concurrent neurotoxicity and ototoxicity warran- 
ting removal from study. In 12 other responding patients, 
treatment was stopped because of the development of ei- 
ther ototoxicity (nine patients) or neuropathy (three pa- 
tients). One responding patient refused to travel to our 
center and was taken off study. One patient with bulky un- 
resectable disease achieved maximum response (PR) after 
three courses and was taken off study to receive full-course 
radiotherapy. No patient was removed from study because 
of nephrotoxicity. Disease progression was noted within 2 
months of stopping cisplatin in all patients. The median 
survival time of the 16 recurrent disease patients was 33.5 
weeks (range 18-66 weeks). The median survival time of 
the six newly diagnosed patients was 108 weeks (range 
21-121 + weeks). 
D i s c u s s i o n  
The armamentarium of useful drugs to treat head and neck 
malignancies is very limited. Cisplatin is one of the few 
agents that have been studied closely enough to establish 
the response rate and limiting toxicities in conventional 
dosage regimens. This trial demonstrated the feasibility of 
administering a 200-mg/m 2 divided dose to head and neck 
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cancer patients. The method of  hydration was less vigo- 
rous than that used by other investigators [1, 9]. The inci- 
dence of  acute, reversible, nephrotoxicity was 18%. In all 
four patients, serum creatinine elevation occurred after the 
first cycle and returned to normal. Litterst has postulated 
that administration of  cisplatin in hypertonic saline lowers 
binding to plasma proteins and tissue binding sites with re- 
sultant decrease in nephrotoxicity [8]. The smaller daily 
dose and vigorous hydration, including the diuretic effects 
o f  3% NaC1, may play a significant role in this protective 
renal effect. Clearly this mechanism does not protect 
against other toxicities. Ototoxicity and neuropathy were 
the major  toxicities observed, resulting in the early with- 
drawal of  12 responding patients after a median of  three 
courses (range one to four courses). Of  note is the fact that 
three o f  the four patients who tolerated four or five courses 
before the development of  limiting toxicity underwent  
dose reductions to 150 m g / m  2. Myelosuppression was ma- 
nageable and also not treatment-limiting. 
Of  great importance was the response rate observed in 
this trial. The 73% CR + PR rate was nearly double the ex- 
pected 30%-40% reported in similar patients treated with 
standard doses of  cisplatin. Further, the activity observed 
in patients who were unresponsive or refractory to lower 
doses supports a dose-response effect for cisplatin in this 
disease. No  differences in response rate or toxicity were 
evident between the 4-day and 5-day schedules, although 
patient numbers are small. 
The response duration could be assessed in only two 
patients who continued on treatment until progressive dis- 
ease was documented at 3 and 4 months after achieving 
PR and CR status. Disease recurred in all other responders 
with recurrent disease within 2 months o f  stopping cisplat- 
in. The lack of  a higher CR rate in these patients was dis- 
appointing. This may in part  be due to the characteristics 
of  the patient population, large tumor  bulk, and extensive 
prior treatment. It is interesting that the one pathologically 
confirmed CR was in a previously untreated patient. 
Based on these results the maximum number  o f  toler- 
able courses is limited to three, and we would therefore see 
no role for high-dose cisplatin in the palliative treatment 
o f  head and neck cancer. An appropriate role for high- 
dose cisplatin may be in the adjuvant treatment of  poten- 
tially curable patients. 
In summary,  high-dose cisplatin with hypertonic saline 
results in a high response rate in both recurrent disease 
and newly diagnosed patients. Administration of  cisplatin 
with 3% NaC1, hydration, and in divided doses amelio- 
rates nephrotoxicity but affords no protection against 
other toxicities. Neuropathy and ototoxicity are dose-li- 
miting. Further evaluation of  its role in a combined mo- 
dality approach seems warranted. 
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